Literature DB >> 15729714

Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin.

Erica Miraglia1, Daniele Viarisio, Chiara Riganti, Costanzo Costamagna, Dario Ghigo, Amalia Bosia.   

Abstract

Multidrug resistant (MDR) tumor cells exhibit an altered pH gradient across different cell compartments, which favors a reduced intracellular accumulation of antineoplastic drugs and a decreased therapeutic effect. In our study, we have observed that the activity and expression of Na+/H+ exchanger (NHE), which is involved in the homeostasis of intracellular pH (pHi), are increased in doxorubicin-resistant (HT29-dx) human colon carcinoma cells in comparison with doxorubicin-sensitive HT29 cells. The pH(i) was significantly higher in HT29-dx cells, which accumulated less doxorubicin than HT29 cells. The NHE inhibitor 5-(N-ethyl-N-isopropyl)amiloride (EIPA) significantly reduced the pHi value and increased the intracellular accumulation of doxorubicin in both cell populations: in the presence of EIPA HT29-dx cells accumulated as much drug as control HT29 cells. On the other hand, monensin, a Na+/H+ ionophore mimicking NHE activation, and phorbol 12-myristate 13-acetate (PMA), which stimulates NHE, significantly increased the pHi and decreased the drug accumulation in HT29 cells to values similar to those observed in control HT29-dx cells. EIPA potentiated the cytotoxic effect of doxorubicin in HT29 cells, and made HT29-dx cells as sensitive to the cytotoxic effect of the drug as control HT29 cells. Instead, PMA and monensin made HT29 cells as insensitive to doxorubicin as HT29-dx cells. These results suggest that in MDR cells the higher cytosolic pH is likely to decrease drug accumulation, and that such resistance can be reverted by inhibiting the NHE activity. This result opens the possibility to revert MDR with the clinical use of NHE inhibitors. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15729714     DOI: 10.1002/ijc.20959

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

Review 1.  Dysregulated pH: a perfect storm for cancer progression.

Authors:  Bradley A Webb; Michael Chimenti; Matthew P Jacobson; Diane L Barber
Journal:  Nat Rev Cancer       Date:  2011-08-11       Impact factor: 60.716

Review 2.  Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades.

Authors:  Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 3.  Drug resistance and cellular adaptation to tumor acidic pH microenvironment.

Authors:  Jonathan W Wojtkowiak; Daniel Verduzco; Karla J Schramm; Robert J Gillies
Journal:  Mol Pharm       Date:  2011-10-26       Impact factor: 4.939

Review 4.  Role of pHi, and proton transporters in oncogene-driven neoplastic transformation.

Authors:  Stephan Joel Reshkin; Maria Raffaella Greco; Rosa Angela Cardone
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-02-03       Impact factor: 6.237

5.  Lower Lactate Levels and Lower Intracellular pH in Patients with IDH-Mutant versus Wild-Type Gliomas.

Authors:  K J Wenger; J P Steinbach; O Bähr; U Pilatus; E Hattingen
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-09       Impact factor: 3.825

Review 6.  The Na+/H+ exchanger NHE1 in stress-induced signal transduction: implications for cell proliferation and cell death.

Authors:  Stine Falsig Pedersen
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

7.  Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil.

Authors:  Milica Pesić; Ana Podolski; Ljubisa Rakić; Sabera Ruzdijić
Journal:  Invest New Drugs       Date:  2009-06-18       Impact factor: 3.850

8.  Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms.

Authors:  Tingjun Lei; Supriya Srinivasan; Yuan Tang; Romila Manchanda; Abhignyan Nagesetti; Alicia Fernandez-Fernandez; Anthony J McGoron
Journal:  Nanomedicine       Date:  2010-11-19       Impact factor: 5.307

Review 9.  How Dysregulated Ion Channels and Transporters Take a Hand in Esophageal, Liver, and Colorectal Cancer.

Authors:  Christian Stock
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

10.  An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS).

Authors:  Salvador Harguindey; Gorka Orive; Ramón Cacabelos; Enrique Meléndez Hevia; Ramón Díaz de Otazu; Jose Luis Arranz; Eduardo Anitua
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.